<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514345</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-PK-2007-02</org_study_id>
    <secondary_id>CDR0000560128</secondary_id>
    <secondary_id>EU-20743</secondary_id>
    <nct_id>NCT00514345</nct_id>
  </id_info>
  <brief_title>CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide</brief_title>
  <official_title>CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer
      treated with ifosfamide may help doctors identify risk factors for kidney damage.

      PURPOSE: This clinical trial is looking at the CYP3A5 gene to see if having the gene may be a
      risk factor for kidney damage in young patients with cancer treated with ifosfamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the CYP3A5 genotype in young patients with cancer who have received
           ifosfamide.

        -  To document renal function and nephrotoxicity on one occasion between 1 month and 5
           years after completion of ifosfamide treatment.

        -  To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity.

      Secondary

        -  To compare the measured glomerular filtration rate (GFR) (using a radioisotope clearance
           method) with that calculated using the Cole (weight and creatinine) model.

      OUTLINE: This is a multicenter study.

      Nephrotoxicity assessment is performed in patients who have not undergone prior assessment*.

      NOTE: *Nephrotoxicity assessment is performed once between 1 month and 5 years after
      completion of ifosfamide chemotherapy.

      All patients will undergo a single blood sample collection. DNA will be extracted from this
      sample and genotyped for the known functional polymorphisms in CYP3A5. The technique of
      restriction fragment length polymorphism (RFLP) will be used to detect any single nucleotide
      polymorphisms in CYP3A5.

      DNA may be obtained from stored tumor samples from patients for whom the results of renal
      investigations are available, but for whom blood is not available for CYP3A5 genotyping.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>CYP3A5 genotype</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function and nephrotoxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between CYP3A5 genotype and ifosfamide nephrotoxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of measured glomerular filtration rate (GFR) with the Cole model</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Received ifosfamide before the age of 21 as part of treatment for cancer including,
             but not limited to, any of the following:

               -  Ewing sarcoma

               -  Rhabdomyosarcoma

               -  Non-rhabdomyosarcoma soft tissue sarcoma

          -  No renal infiltration by tumor at any stage of illness

          -  May have been treated on one of the following clinical trials:

               -  Euro-Ewing-Intergroup-EE99

               -  SIOP-MMT-95

                    -  Patients who received CEV chemotherapy (carboplatin, epirubicin, and
                       vincristine) on strategy 952 or 953 are not eligible

               -  CCLG-EPSSG-NRSTS-2005

               -  CCLG-EPSSG-RMS-2005

        PATIENT CHARACTERISTICS:

          -  Clinically stable to undergo renal investigations

          -  No pre-existing renal impairment (glomerular or tubular) prior to treatment with
             ifosfamide

          -  No known nephrotoxicity for which nephrotoxic supportive treatment (aminoglycosides,
             amphotericin, acyclovir, cyclosporine, or tacrolimus) was a major contributory cause
             of renal damage

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from the acute non-renal toxicity of the last course of chemotherapy

          -  No other prior nephrotoxic chemotherapy (e.g., cisplatin, carboplatin, melphalan, or
             high-dose methotrexate)

          -  No prior radiotherapy to a field including the kidneys

          -  No prior removal of renal tissue

          -  No concurrent ifosfamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gareth Veal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Newcastle Upon-Tyne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>353-1-409-6659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin W. English, MD</last_name>
      <phone>44-121-333-8412</phone>
      <email>martin.english@bch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-342-0205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Burke, MD</last_name>
      <phone>44-1223-348-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Glaser, MD</last_name>
      <phone>44-113-206-4984</phone>
      <email>adam.glaser@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Visser, MD</last_name>
      <phone>44-116-258-5309</phone>
      <email>johannes.visser@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather P. McDowell, MD</last_name>
      <phone>44-151-293-3679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PCE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Michelagnoli, MD</last_name>
      <phone>44-20-7380-9064</phone>
      <email>maria.michelagnoli@uclh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gill Levitt, MD</last_name>
      <phone>44-20-7405-9200 ext. 0073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Brennan, MD</last_name>
      <phone>44-161-922-2227</phone>
      <email>bernadette.brennan@cmmc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Hale, MD</last_name>
      <phone>44-191-282-4101</phone>
      <email>j.p.hale@ncl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hewitt, MD, BSc, FRCP, FRCPCH</last_name>
      <phone>44-115-924-9924 ext. 63394</phone>
      <email>martin.hewitt@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Wheeler, MD</last_name>
      <phone>44-186-522-1066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary P. Gerrard, MBChB, FRCP, FRCPCH</last_name>
      <phone>44-114-271-7366</phone>
      <email>mary.gerrard@sch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice A. Kohler, MD, FRCP</last_name>
      <phone>44-23-8079-6942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Taj, MD</last_name>
      <phone>44-20-8642-6011 ext. 3089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony McCarthy, MD</last_name>
      <phone>44-289-063-3631</phone>
      <email>anthonymcarthy@royalhospital.n.i.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Neefjes</last_name>
      <phone>44-1224-550-217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Hamish Wallace, MD</last_name>
      <phone>44-131-536-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind D. Ronghe, MD</last_name>
      <phone>44-141-201-9309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Traunecker, MD, PhD</last_name>
      <phone>44-29-2074-2285</phone>
      <email>heidi.traunecker@cardiffandvale.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>localized Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

